Q-omics provides the consensus-scored MSANTD1 profile across patient tissues and cancer cell-line models. MSANTD1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MSANTD1 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, MSANTD1 RNA expression shows 17,603 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, LIHC, and UVM as cancer lineages where MSANTD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSANTD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSANTD1 survival associations across molecular data types. MSANTD1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSANTD1 RNA expression–survival associations across cancer types. High MSANTD1 expression shows unfavorable associations in KIRC, ACC and COAD, but favorable associations in SKCM, LUAD and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MSANTD1 RNA expression.
This table summarizes MSANTD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MSANTD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSANTD1 shows lower tumor expression in THCA, KIRC and LUSC and higher tumor expression in LIHC, UCEC and BRCA. The LIHC box plot shows higher MSANTD1 RNA expression in tumor versus normal tissue (log2 FC = +0.081, t-test p < 0.001).
This table shows molecular features associated with MSANTD1 in patient tissues and cancer cell lines. In patient samples, MSANTD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MSANTD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
